Study Stopped
The corona virus pandemic\_UK national lockdown
Validation of Cognitive Screenings for the Hearing Impaired
Validation of "Montreal Cognitive Assessment (MoCA) and Addenbrooke's Cognitive Examination III (ACE-III) "as a Cognitive Screening Tools for the Hearing Impaired
1 other identifier
interventional
78
1 country
2
Brief Summary
There are currently no cognitive tests that have been validated as screening tools for people with dementia and comorbid hearing loss. This is particularly important given the high prevalence of hearing impairment in older adults presenting to memory services and the risk of misdiagnosis of dementia in this population as outlined above. Cognitive tests validated in hearing impaired populations will also be important as outcome tools for interventional research aiming to find out if treating hearing loss may reduce dementia risk in the longer term.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Nov 2018
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 2, 2018
CompletedFirst Posted
Study publicly available on registry
August 27, 2018
CompletedStudy Start
First participant enrolled
November 9, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 13, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
March 13, 2020
CompletedNovember 9, 2020
November 1, 2020
1.3 years
August 2, 2018
November 5, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
The adapted version Montreal Cognitive Assessment (MoCA) questionnaire total score among dementia/mild cognitive impairment/normal cognition group of hearing impaired older adult.
The score will be used to calculate the appropriate cut-point score for differentiating each group of hearing impaired older adults.(total score ranging from 0-30 points with higher score indicate better cognitive function)
approximately 1 years (expected to recruit 30 participants for each group)
The adapted version Addenbrooke's Cognitive Examination III (ACE-III) questionnaire total score among dementia/mild cognitive impairment/normal cognition group of hearing impaired older adult.
The score will be used to calculate the appropriate cut-point score for differentiating each group of hearing impaired older adults (total score ranging from 0-100 points with higher score indicate better cognitive function)
approximately 1 years (expected to recruit 30 participants for each group)
Secondary Outcomes (1)
Hearing handicap score from the Modified Amsterdam Inventory for Auditory Disability and Handicap (mAIAD) (total score ranging from 0-84 with higher score indicate smaller perceived hearing difficulty)
approximately 1 years (expected to recruit 30 participants for each group)
Other Outcomes (1)
Final cognitive status diagnosis (base on ICD-10 coding system; dichotomous outcome; code F00-F03 (dementia) or code ICD F06.7 (Mild cognitive impairment)) provided by an NHS memory service doctors at routine clinical care follow up session at 1 year.
1 year follow up from initial recruitment
Study Arms (3)
dementia (D-HI)
EXPERIMENTALhearing impaired dementia
Mild cognitive impairment (MCI-HI)
OTHERMCI with hearing loss
normal (N-HI)
ACTIVE COMPARATORnormal cognition with hearing loss
Interventions
Several cognitive and hearing (peripheral and (central) auditory process) tests
Eligibility Criteria
You may qualify if:
- Age over 65 years
- Documented Hearing loss (currently wearing hearing aids and/or hearing testing with a hearing average of \>/= 30dB HL in D-HI,MCI-HI group)
You may not qualify if:
- Uncorrected visual impairment; cognitive and/or physical disability(s) which prevent the performance of the written/drawing elements of the tests, in the opinion of the researcher.
- Severe to profound hearing loss (PTA \>70dBHL)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Royal National Throat Nose Ear Hospital
London, WC1X 8DA, United Kingdom
Camden and Islington NHS memory service
London, United Kingdom
Related Publications (2)
MacDonald AA, Joyson A, Lee R, Seymour DG, Soiza RL. The effect of hearing augmentation on cognitive assessment scales at admission to hospital. Am J Geriatr Psychiatry. 2012 Apr;20(4):355-61. doi: 10.1097/JGP.0b013e3182107e88.
PMID: 22434018RESULTLin FR, Yaffe K, Xia J, Xue QL, Harris TB, Purchase-Helzner E, Satterfield S, Ayonayon HN, Ferrucci L, Simonsick EM; Health ABC Study Group. Hearing loss and cognitive decline in older adults. JAMA Intern Med. 2013 Feb 25;173(4):293-9. doi: 10.1001/jamainternmed.2013.1868.
PMID: 23337978RESULT
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Nattawan Utoomprurkporn, MD,Msc
University College, London
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- DIAGNOSTIC
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 2, 2018
First Posted
August 27, 2018
Study Start
November 9, 2018
Primary Completion
March 13, 2020
Study Completion
March 13, 2020
Last Updated
November 9, 2020
Record last verified: 2020-11
Data Sharing
- IPD Sharing
- Will not share
only share within researchers team